Kiran S. Divi

We do not foresee any disruption because, and it's in line with whatever our double-digit growth that we keep talking about.

We are currently executing three major CapEx programs backed by long-term supply commitments.

Divi's has strategically decided that we will not look at generic part of peptide synthesis. We are right now fully occupied with the amount of CS projects we have.

We have successfully maintained stable volumes in all our core products.

A significant recent highlight was the signing of a long-term manufacturing and supply agreement for an Advanced Intermediate with a leading global pharmaceutical company.

We are witnessing a rise in customer engagement reflected in an increased number of RFPs and on-site visits.

In this GLP-1s, right now, the way things are looking, sky is the limit.

We are not only expanding our market presence but also reinforcing our reputation as a trusted partner in complex and high-value green chemistry.

In the peptide segment, we are very optimistic that we will be a major player in the long term.

I would say about year-on-year, we would have a 20%-30% increase in volume would be a fair statement.

We are seeing a huge amount of growth and a lot of opportunities coming on our side, especially since there is a direction that the Big Pharma should work more with Indian companies and towards European companies.

We have not lost any market share. In fact, we have gained market share in several of our large volume APIs.